Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database

5 Sept 2023

Abstract excerpt

Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the Canadian Myeloma Research Group (CMRG) national database, we examined the details and outcomes of ASCT performed as first-line therapy in eligible Canadian MM patients between 2007 to 2021. We included 3821 patients with 72% receiving CyBorD induction and 2061...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37669949
DOI: 10.1038/s41408-023-00905-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databasePMID 37669949Read ↗

Second Primary Malignancies Post Autologous Stem-cell Transplant in Multiple Myeloma from India – Knowing the UnknownSemantic proximity Read ↗

Establishing Measurable Residual Disease Trajectories for Patients on Treatment for Newly Diagnosed Multiple Myeloma as Benchmark for Deployment of T-cell Redirection TherapySemantic proximity Read ↗

The future of autologous stem cell transplantation in myelomaSemantic proximity Read ↗

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationSemantic proximity Read ↗

Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or olderSemantic proximity Read ↗

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersSemantic proximity Read ↗

Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantationSemantic proximity Read ↗

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal AntibodySemantic proximity Read ↗

Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patientsSemantic proximity Read ↗

Impact of Daratumumab in Transplant Eligible/Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Meta-Analysis of Phase- III TrialsSemantic proximity Read ↗

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained responseSemantic proximity Read ↗

Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.